China Aflibercept Market Survey Report 2022: Annual growth rate in 2021 was 116%, which slowed down due to the COVID-19 outbreak

0

DUBLIN, August 9, 2022 /PRNewswire/ — The “Investigation report on China Aflibercept Market 2022-2031″ report has been added to from ResearchAndMarkets.com offer.

Aflibercept is an anti-VEGF drug, primarily used to treat neovascular age-related macular degeneration (AMD) and other retinopathies caused by visual impairment. Aflibercept was jointly developed by Regeneron and Bayer. Regeneron has exclusive sales rights in the US market, while Bayer obtains exclusive sales rights outside the US Their Aflibercept, EYLEA was launched in China in 2018. By July 2022Bayer AG is the only manufacturer on the Chinese market of Aflibercept.

According to this market research, after Aflibercept entered the Chinese market, the sales value of Aflibercept in China increases by CNY8.3 million in 2018 at 238 million yuan in 2021. The annual growth rate in 2021 was 116%, which has slowed down due to the COVID-19 epidemic. The CAGR of the sales value of aflibercept in China is 206% from 2018 to 2021.

The analyst analyzes that as the epidemic situation has improved and hospitals resume their operations, the sales of Aflibercept will experience recovery growth from 2023 to 2026. In addition, the sales will also increase due to the market expansion. Currently, China approved only two indications for Aflibercept, including the treatment of AMD and the treatment of DME.

However, Aflibercept had five indications approved worldwide, which means that sales will continue to grow as the number of indications increases. On the other hand, although the anti-VEGF ophthalmic drug market to which Aflibercept belongs accounts for the largest market share in the ophthalmic drug industry, the penetration rate of the anti-VEGF drug is still low.

The penetration rate of the anti-VEGF drug is about 1% in China, while it exceeds 5% in the USA Market demand has not yet reached saturation, sales will continue to increase. In addition, Aflibercept was included in the national health insurance catalog at the beginning of 2020, so the price was lowered, which reduces the burden on patients and will boost sales in the future.

Qilu Pharmaceutical, a local Chinese pharmaceutical company, has received CDE (CENTER FOR DRUG EVALUATION, NMPA) approval for its marketing authorization application for the intravitreal injection of aflibercept in April 2022which is the first biosimilar application of aflibercept in China.

According to this market research, a number of other pharmaceutical companies China are generating aflibercept, such as Clover Biopharmaceuticals’ aflibercept intraocular injection, which is in the clinical stage of application, and Shandong Boan Biotechnology Co.

The generic version of aflibercept is expected to enter the Chinese market within the next five years, but it is unlikely to have a significant impact on Bayer’s original drug in the short term.

Topics Covered:

  • The impact of COVID-19 on China aflibercept market
  • Sales value and volume of China aflibercept 2016-2020
  • Competitive landscape of China aflibercept market
  • aflibercept price in China
  • aflibercept price in China by regions and manufacturers
  • Analysis of factors affecting the development of China aflibercept market
  • Prospect of China aflibercept market from 2021 to 2025

Main topics covered:

1 Relevant concepts of Aflibercept
1.1 Indications for Aflibercept
1.2 Development of Aflibercept in China
1.3 Government approval of Aflibercept in China
1.4 The impact of COVID-19 on Aflibercept sales in China

2 Aflibercept sales in China2018-2021
2.1 Commercial value of Aflibercept
2.1.1 Overall sales value
2.1.2 Sales Value by Region
2.2 Aflibercept Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Aflibercept Sales by Dosage Form in China2018-2021
2.3.1 Intraocular injection
2.3.2 Analysis of other dosage forms

3 Aflibercept Major Manufacturers Analysis China2018-2021

3.1 Aflibercept Major Manufacturers Market Share Analysis
3.1.1 Market Share Survey by Sales Value
3.1.2 Market Share Survey by Sales Volume
3.2 Bayer AG
3.2.1 Company profile
3.2.2 Sales of EYLEA (Aflibercept by Bayer) in China

4 Aflibercept Prices for Different Manufacturers in China2021-2022
4.1 Bayer AG (EYLEA)
4.2 Others

5 China Aflibercept Drugs Market Outlook, 2022- 2031
5.1 Influencing Factors of China Aflibercept Market Development
5.1.1 The impact of COVID-19 on the Chinese Aflibercept market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast

For more information on this report, visit https://www.researchandmarkets.com/r/wo7u36

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

Share.

Comments are closed.